Adjunctive Therapy of Exenatide or Sitagliptin to Insulin Glargine in Type 2 Diabetes
Status:
Completed
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
This study investigated a 4-week adjunctive therapy of either a GLP-1 analog (exenatide), or
a DPP-4 inhibitor (sitagliptin), given to a basal insulin analog (insulin glargine), and
their effect on blood glucose control, versus insulin glargine alone as active comparator in
type 2 diabetes.